Drug Profile
Flanvotumab
Alternative Names: 20D7; 20D7S; IMC 20D7SLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action TYRP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (Parenteral)
- 06 Apr 2012 ImClone completes enrolment in its phase I trial for Malignant melanoma in the US (NCT01137006)
- 17 Jun 2010 Phase-I clinical trials in Malignant melanoma in USA (Parenteral)